Rostafuroxin

• CAT Number: I001990
• CAS Number: 156722-18-8
• Molecular Formula: C23H34O4
• Molecular Weight: 374.5
• Purity: ≥95%
• Target: Sodium Channel
• Solubility: 10 mM in DMSO
• Storage: Store at -20°C
• IC50: 1.5 nM [1]
• InChI: InChI=1S/C23H34O4/c1-20-8-5-17(24)13-15(20)3-4-19-18(20)6-9-21(2)22(25,10-11-23(19,21)26)16-7-12-27-14-16/h7,12,14-15,17-19,24-26H,3-6,8-11,13H2,1-2H3/t15-,17+,18+,19-,20+,21-,22+,23+/m1/s1
• InChIKey: AEAPORIZZWBIEX-DTBDINHYSA-N
• SMILES: O[C@H]1CC[C@@]2(C)[C@@](CC[C@]3([H])[C@]2([H])CC[C@@]4(C)[C@]3(O)CC[C@]4(O)C5=COC=C5)([H])C1

Rostafuroxin (Cat.No:I001990) is a compound known for its antihypertensive properties. It acts as a potent antagonist of the α1-Na⁺/K⁺ ATPase isoform, which regulates sodium and potassium transport in cells. Rostafuroxin has shown potential in preclinical studies for the treatment of hypertension by modulating ion transport and cardiovascular function.

Reference

1:Rostafuroxin protects from podocyte injury and proteinuria induced by adducin genetic variants and ouabain. Ferrandi M, Molinari I, Rastaldi MP, Ferrari P, Bianchi G, Manunta P.J Pharmacol Exp Ther. 2014 Nov;351(2):278-87. doi: 10.1124/jpet.114.217133. Epub 2014 Sep 3. PMID: 25187430 Free Article2:Rostafuroxin ameliorates endothelial dysfunction and oxidative stress in resistance arteries from deoxycorticosterone acetate-salt hypertensive rats: the role of Na+K+-ATPase/ cSRC pathway. Wenceslau CF, Rossoni LV.J Hypertens. 2014 Mar;32(3):542-54. doi: 10.1097/HJH.0000000000000059. PMID: 24309491 3:Main results of the ouabain and adducin for Specific Intervention on Sodium in Hypertension Trial (OASIS-HT): a randomized placebo-controlled phase-2 dose-finding study of rostafuroxin. Staessen JA, Thijs L, Stolarz-Skrzypek K, Bacchieri A, Barton J, Espositi ED, de Leeuw PW, Dłużniewski M, Glorioso N, Januszewicz A, Manunta P, Milyagin V, Nikitin Y, Souček M, Lanzani C, Citterio L, Timio M, Tykarski A, Ferrari P, Valentini G, Kawecka-Jaszcz K, Bianchi G.Trials. 2011 Jan 14;12:13. doi: 10.1186/1745-6215-12-13. PMID: 21235787 Free PMC Article4:Adducin- and ouabain-related gene variants predict the antihypertensive activity of rostafuroxin, part 2: clinical studies. Lanzani C, Citterio L, Glorioso N, Manunta P, Tripodi G, Salvi E, Carpini SD, Ferrandi M, Messaggio E, Staessen JA, Cusi D, Macciardi F, Argiolas G, Valentini G, Ferrari P, Bianchi G.Sci Transl Med. 2010 Nov 24;2(59):59ra87. doi: 10.1126/scitranslmed.3001814. PMID: 21106941 Free Article5:Adducin- and ouabain-related gene variants predict the antihypertensive activity of rostafuroxin, part 1: experimental studies. Ferrandi M, Molinari I, Torielli L, Padoani G, Salardi S, Rastaldi MP, Ferrari P, Bianchi G.Sci Transl Med. 2010 Nov 24;2(59):59ra86. doi: 10.1126/scitranslmed.3001815. PMID: 21106940 Free Article6:Rostafuroxin: an ouabain-inhibitor counteracting specific forms of hypertension. Ferrari P.Biochim Biophys Acta. 2010 Dec;1802(12):1254-8. doi: 10.1016/j.bbadis.2010.01.009. Epub 2010 Jan 18. Review. PMID: 20083196 Free Article7:Rostafuroxin: an ouabain antagonist that corrects renal and vascular Na+-K+- ATPase alterations in ouabain and adducin-dependent hypertension. Ferrari P, Ferrandi M, Valentini G, Bianchi G.Am J Physiol Regul Integr Comp Physiol. 2006 Mar;290(3):R529-35. Review. PMID: 16467500 Free Article